|
Affiliation |
Graduate School of Medicine Doctorial Course in Medicine Oncoregulatory Medicine Department of Hematology,Nephrology,and Rheumatology |
|
Date of Birth |
1964 |
|
Laboratory Address |
Dept. Hematology, Akita Univ. |
|
Laboratory Phone number |
+81-18-884-6115 |
|
Laboratory Fax number |
+81-18-836-2613 |
|
Mail Address |
|
TAKAHASHI Naoto
|
|
|
Research Interests 【 display / non-display 】
-
Hematology
-
血液腫瘍学
-
分子細胞遺伝学
-
薬物動態
-
薬物遺伝学
Graduating School 【 display / non-display 】
-
-1997
Akita University Graduated
-
-1997
Akita University Graduated
-
-1990.03
Akita University Faculty of Medicine Graduated
-
-1990
Akita University Faculty of Medicine Graduated
-
-1990
Akita University Faculty of Medicine School of Medicine Graduated
Graduate School 【 display / non-display 】
-
-1997.03
Akita University Graduate School,Division of Medicine Doctor's Course Completed
Studying abroad experiences 【 display / non-display 】
-
2003.05-2005.09
Saskatoon Cancer Centre, University of Saskatchewan Postdoctoral Research Fellowship
Campus Career 【 display / non-display 】
-
2015.02-Now
Akita University Graduate School of Medicine Doctorial Course in Medicine Oncoregulatory Medicine Professor
-
2006.04-2015.01
Akita University School of Medicine School of Medicine Lecturer
External Career 【 display / non-display 】
-
2015.02
Akita University Graduate School of Medicine Professor
Research Areas 【 display / non-display 】
-
Life Science / Hematology and medical oncology
-
Life Science / Hematology and medical oncology
Research Achievements 【 display / non-display 】
-
Ayano Saito, Yoshihiro Kameoka, Kumi Ubukawa, Hiroshi Ohtani, Fumito Abe, Masaya Saito, Mako Hashimoto, Tatsuro Kanazawa, Atsushi Komatsuda, Naoto Takahashi
Internal medicine (Tokyo, Japan) ( 一般社団法人 日本内科学会 ) advpub ( 0 ) 2024.10
Research paper (journal)
A 71-year-old woman developed nephrotic syndrome during 10-year follow-up for chronic lymphocytic leukemia. A renal biopsy sample analysis revealed IgG1-lambda-positive monoclonal immunotactoid glomerulopathy (mITG). The patient was treated with ibrutinib, a Bruton tyrosine kinase inhibitor, and complete renal remission was achieved after 24 months. ITG is a rare disease that is characterized by glomerular deposition. In particular, mITG, which presents immune deposits that exhibit light-chain restriction, is often associated with hematologic disorders. Most patients with mITG receive immunosuppressive therapy and/or chemotherapy; however, to our knowledge, there have been no reports of treatment with ibrutinib.
-
Ponatinib Improved the Prognosis of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Japanese Single-Center Cohort Study.
Nagi Tozawa, Takaya Yamashita, Miho Nara, Yuki Fujioka, Sho Ikeda, Takahiro Kobayashi, Isuzu Kobayashi, Akihiro Kitadate, Yoshihiro Kameoka, Naoto Takahashi
Cureus 15 ( 12 ) e50416 2023.12
Research paper (journal)
Introduction The overall survival (OS) of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) has improved with the combination of tyrosine kinase inhibitor (TKI) with intensive chemotherapy. In recent years, there has been increased interest in the possibility of long-term survival without allogeneic hematopoietic stem cell transplantation (HSCT) or maintenance therapy. The aim of this study was to determine the effectiveness of treatment and the resultant outcomes in Ph+ALL patients using real-world data. Methods We performed a single-center retrospective analysis utilizing Akita University Hospital data (Akita, Japan) from November 2000 to June 2023 to evaluate the outcomes of TKI with intensive chemotherapy for Ph+ALL. Results Twenty-three patients with Ph+ALL were treated with intensive chemotherapy combined with TKI, including six imatinib, four dasatinib, and 13 ponatinib. The median patient age was 53 years (range; 28-67). Eighteen patients (78%) achieved complete molecular remission (CMR) within three months. HSCT was performed in 16 patients (70%), all of whom did not receive post-transplant TKI maintenance therapy. Six of the seven patients who did not undergo HSCT received maintenance therapy with ponatinib after intensive chemotherapy. The three-year OS was 81%. Ponatinib treatment resulted in a much higher OS rate than imatinib/dasatinib (100% vs. 60%; P=0.011). CMR within three months was identified as a prognostic factor for molecular relapse-free survival (hazard ratio (HR)=0.22; P=0.027). CD20 positivity was identified as a risk factor for hematological relapse (HR=5.2, P=0.032). Conclusion Even in a single-center cohort study, ponatinib, as a combination TKI with intensive chemotherapy or maintenance therapy, may improve the prognosis of Ph+ALL. Patients with CMR within three months might not necessarily need to receive HSCT, but a subsequent treatment-free status could have been achieved only by HSCT. Furthermore, CD20 positivity may be a useful biomarker for future treatment decisions in patients with Ph+ALL.
-
Abumiya M.
Journal of Clinical Pharmacy and Therapeutics ( Journal of Clinical Pharmacy and Therapeutics ) 46 ( 2 ) 382 - 387 2021.04 [Refereed]
Research paper (journal) Domestic Co-author
-
Abumiya M.
Journal of Clinical Pharmacy and Therapeutics ( Journal of Clinical Pharmacy and Therapeutics ) 46 ( 1 ) 219 - 222 2021.02 [Refereed]
Research paper (journal) Domestic Co-author
-
Ito F.
International Journal of Hematology ( International Journal of Hematology ) 113 ( 1 ) 100 - 105 2021.01 [Refereed]
Research paper (journal) Domestic Co-author
-
Kumagai Takuya, Saito Masaya, Sato Takahiko, Inoue Junichi, Ishikawa Norihisa, Ono Tsuyoshi, Kono Michihiro, Takahashi Naoto
Internal Medicine ( 一般社団法人 日本内科学会 ) advpub ( 0 ) 2025
<p>We herein report a case of cutaneous squamous cell carcinoma (SCC) characterized by paraneoplastic hypercalcemia-leukocytosis syndrome. The patient presented with systemic symptoms, including anorexia, a fever, and a tumoral lesion on the upper arm. Laboratory test results revealed hypercalcemia and leukocytosis. A tissue biopsy confirmed SCC, and further investigation revealed elevated parathyroid hormone-related protein (PTHrP) and granulocyte-colony stimulating factor (G-CSF) levels. Immunostaining demonstrated G-CSF production by the tumor cells. Radiation therapy was administered, which improved leukocytosis and decreased G-CSF and PTHrP levels. Through a case report and literature review, we explored the clinical characteristics of tumors that produce G-CSF and PTHrP. </p>
-
Successful cord blood transplantation for refractory gamma-delta hepatosplenic T-cell lymphoma developed during treatment of Crohn's disease
SAITO Akihito, NARA Miho, FUJISHIMA Takashi, KUROKI Wataru, YAMASHITA Takaya, KOBAYASHI Takahiro, IKEDA Sho, KITADATE Akihiro, KAMEOKA Yoshihiro, TAKAHASHI Naoto
Rinsho Ketsueki ( The Japanese Society of Hematology ) 65 ( 1 ) 41 - 46 2024
<p>The patient was a 21-year-old man who had been diagnosed with Crohn's disease and received infliximab and azathioprine six years earlier. He was admitted with fever and fatigue. Peripheral blood examination showed LDH 2,473 U/<i>l</i> and thrombocytopenia, and contrast-enhanced computed tomography (CT) showed hepatosplenomegaly. Bone marrow biopsy and liver biopsy showed CD4+CD56+TCR<i>γδ</i>+CD8<sup>−</sup> atypical cells, leading to a diagnosis of hepatosplenic T-cell lymphoma (HSTCL). The patient was refractory to CHOP and DA-EPOCH, and therefore received cord blood transplantation with myeloablative conditioning. CT showed reduced in hepatosplenomegaly and peripheral blood examination showed LDH 165 U/<i>l</i> and plt 180,000/µ<i>l</i>, so the patient was discharged on day117. HSTCL is a tumor of immature <i>γδ</i>T cells with a V<i>δ</i>1 mutation in the spleen, and immunodeficiency has been implicated in its pathogenesis. Patients with inflammatory bowel disease treated with azathioprine are known to have an increased risk of lymphoproliferative disease. In this case, use of immunosuppressive drugs for Crohn's disease may have caused malignant transformation of <i>γδ</i> cells in the intestinal epithelium. Although the patient was refractory to chemotherapy, he was able to achieve remission with early cord blood transplantation and long-term survival is expected.</p>
-
Kobayashi Takahiro, Honami Sato, Miura Masatomo, Fukushi Yayoi, Kuroki Wataru, Ito Fumiko, Teshima Kazuaki, Watanabe Atsushi, Fujishima Naohito, Kobayashi Isuzu, Kameoka Yoshihiro, Takahashi Naoto
Cancer Chemotherapy and Pharmacology ( Springer Nature ) 2024
-
t(4;14)陽性多発性骨髄腫に対するMMSET阻害剤
松岡 紗恵, 菊池 次郎, 長田 直希, 窪田 浩一, 喜久里 貢, 小山 裕雄, 菊地 正樹, 安井 寛, 池田 翔, 高橋 直人, 梅原 崇史, 仲宗根 秀樹, 古川 雄祐
日本血液学会学術集会 ( (一社)日本血液学会 ) 85回 44 - 44 2023.10
-
Acute Myeloid Leukemia Harboring the t(16;21)(p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation.
Kazuaki Teshima, Sho Ikeda, Ko Abe, Masahiro Yamada, Naoto Takahashi
Cureus 15 ( 7 ) e42215 2023.07
A 62-year-old female was diagnosed with acute myeloid leukemia (AML) with t(16;21)(p11;q22). She achieved complete hematological remission after induction therapy and underwent umbilical cord blood stem cell transplantation (CBT). At 150 days after the CBT, a bone marrow examination revealed relapse. We treated the patient with venetoclax plus azacitidine as salvage therapy. After five cycles of venetoclax and azacitidine therapy, the patient died due to disease progression. The prognosis of AML with t(16;21)(p11;q22) is very poor owing to the high rate of early relapse even after hematopoietic stem cell transplantation. Therefore, a novel therapeutic approach is required to improve patient outcomes.
◆Original paper【 display / non-display 】
◆Other【 display / non-display 】
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
Grant-in-Aid for Scientific Research(C)
Project Year： 2018.04 - 2022.03
-
The mechanism of organelle relocation in human erythroblasts.
Grant-in-Aid for Scientific Research(C)
Project Year： 2018.04 - 2022.03 Investigator(s): Ubukawa Kumi
-
Grant-in-Aid for Scientific Research(C)
Project Year： 2014.04 - 2018.03
-
Do patients taking tacrolimus need to undergo CYP3A5 genotyping along with blood concentration monitoring?
Grant-in-Aid for Scientific Research(C)
Project Year： 2014.04 - 2018.03 Investigator(s): Niioka Takenori, MIURA Masatomo, SATOH Shigeru, TAKAHASHI Naoto, KAGAYA Hideaki
-
Development of a new treatment strategy using TDM for next generation anticancer drug
Grant-in-Aid for Scientific Research(C)
Project Year： 2014.04 - 2017.03 Investigator(s): Miura Masatomo, Takahashi Naoto, Shibata Hiroyuki, Tsuchiya Norihiko, Kagaya Hideaki, Abumiya Maiko
Acceptance of contract business 【 display / non-display 】
-
Contract period： 2020.04.01 - 2021.03.31
-
Contract period： 2020.04.01 - 2021.03.31
-
Contract period： 2020.04.01 - 2021.03.31